Legal analysis: Fortunately, on July 19, 2017, the Ministry of Human Resources and Social Security issued a notice to include 36 drugs in the scope of medical insurance, among which the targeted tumor treatment drug Sutent was successfully nominated. In other words, Sutent imported from China has been included in medical insurance and is a medical insurance drug.
Although Sutent has greatly reduced the financial burden on patients’ families after entering the medical insurance, the price is still much higher than that of Sutent in India. Even after the current price reduction of medical insurance, it still costs 12,544 yuan per box (50 mg 28 tablets). One bottle is enough for one month. However, this medicine needs to be taken for a long time, so it is difficult for ordinary patients to bear it, so most patients currently use it. Choose to buy Sotent India.
The other version is the Indian version of Sutent. Indian Sutent (sunitinib) is the earliest generic drug of Sutent. It is produced by India's Carbunin. Its ingredients are the same as those of the American patented drug. Same. It was much cheaper at that time. Patients were treated with Sutent, and the monthly cost was around 3,000 yuan.
Legal basis: Article 28 of the "Social Insurance Law of the People's Republic of China" and Drugs Complying with Basic Medical Insurance The directory, diagnosis and treatment items, medical service facility standards, and emergency and rescue medical expenses shall be paid from the basic medical insurance fund in accordance with national regulations.